Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls dom-pubs.pericles-prod.literatumonline.com June 25, 2025, 11:25 a.m.
Patients with type 2 diabetes initiated with metformin monotherapy had longer survival than did matched, non-diabetic controls. Those treated with sulphonylurea had markedly reduced survival compared with both matched controls and those receiving metformin monotherapy. This supports the position of metformin as first-line therapy and implies that metformin may confer benefit in non-diabetes. Sulphonylurea remains a concern.
How Weight-Loss Drugs Blew Out the U.S. Trade Deficit www.wsj.com June 22, 2025, 12:58 p.m.
Shipments have propelled Ireland, a country of 5.4 million, to the second-largest goods-trade imbalance with the U.S., behind China.
Ageing Population: A Catalyst for Healthcare Innovation www.bsigroup.com June 14, 2025, 3:19 p.m.
The considerations posed by an ageing population are indeed substantial, yet shifting demographics also make clear the opportunity to enhance patient outcomes and improve people’s health and lives represented by transformative advancements in healthcare technology. The increasing demand for care has ignited a surge in innovation across healthcare system. From artificial intelligence (AI) and robotics to telemedicine and wearables, there is opportunity to harness technology to enhance the quality of life for all, including those most in need of healthcare interventions, and to bolster the capacity of healthcare providers.
On sait enfin pourquoi l'aspirine prévient les métastases dans certains cancers www.sciencesetavenir.fr June 11, 2025, 7:47 p.m.
Si l'aspirine diminue fortement le risque de certains cancers de se répandre sous forme de métastases, c'est grâce à un gène particulier, inactivé dans certaines cellules immunitaires, ont découvert par hasard des chercheurs.
Artificial Blood That Could Work for All Blood Types in Trials www.newsweek.com June 9, 2025, 10:33 a.m.
The World Health Organization estimates that more than 118 million blood donations are collected each year—with 40 percent coming from high-income countries, home to 16 percent of the world's population. This means a large portion of the global population has limited access to blood transfusion treatment. Universal artificial blood could reduce preventable deaths in injury, surgery and childbirth—settings where supply mismatches or stockouts cost millions of lives annually in low-income nations alone.
Liver Abscess Risk After Biliary Stents in Pancreatic Cancer bioengineer.org June 3, 2025, 8:19 a.m.
In the realm of pancreatic cancer treatment, biliary stent placement has emerged as a vital intervention, offering relief for patients suffering from obstructive jaundice. This procedure, while life-prolonging and often essential, carries with it a significant risk: the development of pyogenic liver abscesses (PLA), a severe and potentially fatal complication. Recent retrospective research brings to light critical insights concerning the incidence, pathology, and management of PLA following biliary stent placement in pancreatic cancer patients, pushing the boundaries of our understanding and underscoring the urgency of heightened clinical vigilance.
Japanese Scientists Created Universal Artificial Blood www.healthcarepackaging.com May 18, 2025, 8:39 p.m.
The artificial blood could be a game-changer for blood transfusions as it can safely be administered to all patients regardless of blood type.
Une nouvelle génération de CAR-T armés pour surmonter les échecs thérapeutiques www.caducee.net May 11, 2025, 4:33 p.m.
Une thérapie cellulaire de nouvelle génération, enrichie en interleukine-18, montre une efficacité notable chez des patients atteints de lymphome B réfractaire, déjà traités par CAR-T anti-CD19. Un espoir renouvelé face aux impasses thérapeutiques.
Enhanced CAR T cell therapy offers new strategy for lymphoma medicalxpress.com May 11, 2025, 4:32 p.m.
A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies. The new therapy diminished cancer in 81% of patients and resulted in complete remission in 52%, with some of the earliest patients treated experiencing durable remission for two years or more.
Digital Health : La digitalisation, incontournable pour la modernisation du secteur pharmaceutique www.lavieeco.com April 21, 2025, 4:13 p.m.
L’essor de l’intelligence artificielle, du Big Data, de la blockchain et de la télémédecine ouvre de nouvelles perspectives pour une médecine plus personnalisée, efficace et accessible. La digitalisation n’est plus une option mais une nécessité stratégique pour améliorer l’efficacité des soins.
Roche stops pivotal TIGIT trial as Keytruda lands knockout blow www.fiercebiotech.com April 19, 2025, 4:18 p.m.
Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting the Swiss drugmaker to stop the study and consider changes to the broader program.
GSK Grabs Rights to Technology That Gets Drugs Across the Blood-Brain Barrier medcitynews.com April 19, 2025, 4:15 p.m.
GSK is licensing an ABL Bio technology that yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease.
Medication Adherence and Deprescribing Programs Aren’t Enough for Today’s Polypharmacy Patients medcitynews.com April 19, 2025, 4:13 p.m.
By moving beyond adherence and drug interactions to a holistic, outcomes-driven approach, health systems and providers can redefine how medication is used — not as a rigid protocol but as a dynamic, patient-centered tool for achieving better health.
Pfizer Stops Work on Oral GLP-1 Obesity Drug After Safety Signal Surfaces in Clinical Trial medcitynews.com April 19, 2025, 4:12 p.m.
Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial.
How the Health Sector Can Change Vaccine Messaging Amid Rising Anti-Vaccine Sentiment medcitynews.com April 19, 2025, 4:10 p.m.
Robert F. Kennedy Jr.’s rise to become secretary of the Department of Health and Human Services has some concerned that anti-vaccine policies are coming. If the nation’s top public health agency pulls support of vaccination, other healthcare stakeholders will need to step up to fill the vaccine messaging void.
DrugOptimal : Une Appli Pour Détecter Les Incompatibilités Médicamenteuses mesinfos.fr March 17, 2025, 8:21 a.m.
Créée en 2022, DrugOptimal développe une application logicielle à destination des établissements de santé, et en particulier des infirmiers et les pharmaciens, pour mieux prévenir les risques d'incompatibilités physicochimiques médicamenteuses.
Revolutionizing Drug Delivery: The Impact of Advanced Materials Science and Technology on Precision Medicine www.mdpi.com March 17, 2025, 8:18 a.m.
The integration of advanced materials into drug delivery systems has become the new normal in pharmaceutical science to address the complexity of modern medicine. These innovations have used technologies such as nanocarriers, hydrogels, and bioresponsive polymers to enable precision, efficiency, and superior therapeutic outcomes. Advanced materials have revolutionized drug delivery by improving upon conventional systems, and their application in various fields, including oncology, chronic disease management, and vaccine delivery, has been remarkable.
Worrying amounts of microplastics found in human brain tissue - how to reduce exposure www.universal-sci.com March 4, 2025, 3:26 p.m.
Microplastics are everywhere—in our water, food, and even the air we breathe. A new scientific review highlights a growing concern: microplastics and nanoplastics are accumulating in human brain tissue. Researchers are now investigating what this could mean for brain health and how we can reduce our exposure.
Takeda's anti-CD38 antibody boosts platelet count in phase 2 www.fiercebiotech.com March 4, 2025, 3:15 p.m.
Last month, the Japanese pharma deprioritized the development of mezagitamab, also known as TAK-079, in myasthenia gravis and systemic lupus erythematosus as part of a wider pipeline shake-up. But the team said at the time that it was still planning to continue to clinically evaluate the antibody in ITP.
Will the Entire NIH be Shut Down? medcitynews.com March 4, 2025, 3:03 p.m.
If you rely on federal grants as your sole means of support, you’re tying your destiny to forces outside your control. There are other roads to success in health and medical research. By pursuing them, you might gain more freedom, fewer administrative hurdles, and the chance to save lives faster.